News
US MCT8 deficiency patients get 1st drug as Emcitate debuts
Egetis has launched the first-ever therapy for the ultra-rare disease MCT8 deficiency in the US, with a list price of $950,000 per year.
News
Novartis takes $1.9bn hit from Avidity takeover in Q3
Novartis's third-quarter results included a $1.9bn impairment relating to its $12bn takeover of Avidity, though CEO insists it remains a good deal.
News
Judge backs Lilly in Novo lawsuit over weight-loss drug ads
A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.
News
Bayer gets first approval for stroke drug asundexian
Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.
Sales & Marketing
Ending rational disengagement: Bridging the strategy-reality...
Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
